AbbVie on Thursday reported second-quarter sales and profit that beat expectations as newer immunology drugs delivered the rapid growth needed to offset plunging sales of blockbuster Humira.
More Stories
The U.S. dollar is weakening ahead of Fed rate cut. This will determine what happens next.
The U.S. dollar has been sliding in the run-up to a widely expected interest-rate cut from the Federal Reserve on...
14 retail stocks that are firing on all cylinders
These retailers have been increasing same-store sales while improving their profit margins
Micron’s stock drops as first ‘death cross’ in 2 years appears
Micron’s stock slumped Monday, just as a longer-term bearish chart pattern appeared for the first time in more than two...
Intel’s stock is shrugging off the chip sector’s weakness. Here’s why.
Intel says a new $3 billion government deal reflects the “continued progress” of its foundry business.
The Fed rate cut could help home buyers solve one of their biggest problems
Falling mortgage rates could ease the ‘lock-in effect’ that’s put a chill on the housing market.
Boeing’s credit rating safe for now, S&P says
While Moody’s Ratings placed the credit on review for a possible downgrade Friday on fears the strike will put more...